1988
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideEvaluation Studies as TopicHumansLeucovorinLeukemiaLeukemia, Radiation-InducedLymph NodesLymphoma, Non-HodgkinMechlorethamineMethotrexateNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedPalliative CarePrednisoneProcarbazineRandom AllocationVincristineConceptsAdvanced indolent lymphomaLimited radiation therapyTotal nodal irradiationIndolent lymphomaRadiation therapyModality treatmentInitial treatmentAggressive combined modality therapyCombined modality therapyEvaluable patientsInduction therapyInitial therapyNodal irradiationFirst remissionInitial remissionFrequent relapsesMedian durationModality therapySystemic therapyCombination chemotherapyMedian timeHistologic progressionLonger survivalPatient's diseasePatientsCytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71: 403-14. PMID: 3337904, DOI: 10.1182/blood.v71.2.403.bloodjournal712403.Peer-Reviewed Original ResearchConceptsChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7Cytogenetic studiesDe novo leukemiaCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapy
1985
Current Management of Hodgkin’s Disease
Behrens B, Young R, DeVita V. Current Management of Hodgkin’s Disease. Drugs 1985, 30: 355-367. PMID: 3905335, DOI: 10.2165/00003495-198530040-00004.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyHodgkin DiseaseHumansLeukemiaLeukemia, Radiation-InducedMechlorethaminePrednisoneProcarbazineVincristineConceptsComplete remissionHodgkin's diseaseDurable complete remissionAcute side effectsCombination chemotherapy programsLong-term complicationsPrognosis of patientsImproved treatment approachesProbable cureInduction therapySalvage therapyMost patientsTerm complicationsChemotherapy programSuch patientsStandard radiotherapySpecific therapySide effectsTreatment approachesPatientsCurrent managementCurrent trialDiseaseTherapyRemission
1983
Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma.
Greene M, Young R, Merrill J, DeVita V. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Research 1983, 43: 1891-8. PMID: 6572558.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsDrug Therapy, CombinationFemaleHumansLeukemia, Myeloid, AcuteLeukemia, Radiation-InducedLung NeoplasmsLymphomaMaleMiddle AgedRadiotherapyRiskSmokingConceptsRisk of acute nonlymphocytic leukemiaNon-Hodgkin's lymphomaAcute nonlymphocytic leukemiaCases of acute nonlymphocytic leukemiaNonlymphocytic leukemiaTherapy of non-Hodgkin's lymphomaNon-Hodgkin lymphoma cohortNon-Hodgkin's lymphoma patientsSingle-modality therapyModel of leukemogenesisCase-control studyCumulative radiation dosePatients per yearOptimum patient managementHemibody radiationLeukemogenic therapyNational Cancer InstituteChemotherapy durationHistological subtypesChemotherapy doseTreatment regimensBone marrowTotal bodyPatient managementTherapy
1977
Risk of new cancers in patients with Hodgkin's disease
Arseneau J, Canellos G, Johnson R, Devita V. Risk of new cancers in patients with Hodgkin's disease. Cancer 1977, 40: 1912-1916. PMID: 907993, DOI: 10.1002/1097-0142(197710)40:4+<1912::aid-cncr2820400823>3.0.co;2-d.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAntineoplastic AgentsFemaleHodgkin DiseaseHumansImmunityLeukemiaLeukemia, Radiation-InducedMaleNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedConceptsHodgkin's diseaseAcute nonlymphocytic leukemiaNew cancersActive Hodgkin's diseaseLong-term complicationsSecond malignant tumorsReports of casesNational Cancer InstituteDirect cellular damageSynergistic carcinogenic effectPotential contributory factorsFurther immunosuppressionUntreated patientsImmunologic abnormalitiesTerm complicationsImproved survivalHD patientsImmunosuppressive factorsNonlymphocytic leukemiaMalignant diseaseMalignant tumorsCancer InstitutePatientsCytotoxic drugsTherapeutic interventions